When was Juvaris founded?

Juvaris was founded in 2001 and raised its 1st funding round 6 years after it was founded.

Where is Juvaris located?

Juvaris is headquartered in Burlingame, United States.

How many employees does Juvaris have?

As of Apr 30, 2026, the latest employee count at Juvaris is 4.

Is Juvaris a funded company?

Juvaris is a funded company, having raised a total of $15.9M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 01, 2007.

When was the latest funding round of Juvaris?

Juvaris' latest funding was a $***** Series B round on Oct 25, 2010, with participation from 0 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.14B in funding in 2026 to date.

Where does Juvaris rank among its competitors?

Juvaris ranks 1445th amongst 3280 active competitors, of which 1122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Juvaris?

Juvaris' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Juvaris - 2026 Company Profile, Team, Funding & Competitors

Company Details

Juvaris BioTherapeutics is developing adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. It offers JVRS-100, a cationic lipid-DNA complex and adjuvant that improves the effectiveness of existing vaccines, as well as helps in developing vaccines against infectious diseases. The company’s product is also used for the treatment of viral, bacterial, and cancer diseases. Juvaris BioTherapeutics has a strategic alliance with Bayer HealthCare AG.

Key Metrics

Founded Year

2001

Location

Burlingame, United States

Stage

Deadpooled

Total Funding

$15.9M in 5 rounds

Latest Funding Round

Series B, Oct 25, 2010, $*****

Investors

SV Health Investors & 3 more

Ranked

1445^th among 3280 active competitors

Employee Count

4 as on Apr 30, 2026

Similar Companies

BeiGene & 583 more

View Juvaris' full profile

Juvaris has raised a total funding of $15.9M over 5 rounds. Its first funding round was on Aug 01, 2007. Juvaris has 4 institutional investors.

Here is the list of recent funding rounds of Juvaris:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 25, 2010	1821465	Series B	5142073	8182950	6595972	4876104
Sep 17, 2009	9489887	Series B	6448127	2636159	7746690	Kleiner Perkins
Sep 25, 2008	5051552	Grant (prize money)	8158541	8889093	5563432	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Juvaris's funding rounds and investors

The founders of Juvaris is Jeff Fairman.

Here are the details of Juvaris' key team members:

Jeff Fairman: Former Co-Founder of Juvaris and founder of 1 other company.
Contact Info: 1 email address

View details of Juvaris's Founder profiles and Board Members

Juvaris' employee count trend

Juvaris has 4 employees as of Apr 26. Here is Juvaris's employee count trend over the years:

Uncover Juvaris' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Juvaris include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Juvaris, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
1445th	Juvaris 2001, Burlingame (United States), Deadpooled	Develops adjuvanted vaccines and immunotherapeutics to treat cancer and infectious diseases	$15.9M	TriplePoint Capital, Kleiner Perkins & 2 others	35/100